| INTRODUCTION
Poly(ADP-ribose) polymerases (PARP) are important DNA repair enzymes. PARP inhibitors (PARPi), including olaparib, rucaparib and niraparib, have been used to treat ovarian cancers defective in DNA homologous recombination repair (HRR) in the clinic. [1] [2] [3] [4] [5] Cancer cells have been shown to develop drug resistance to PARPi, 1 suggesting that their clinical resistance might inevitably emerge from persistent/ repeated treatments. Several mechanisms of PARPi resistance have been reported, including restoration of HRR function due to secondary mutation on BRCA alleles, stabilization of BRCA1 mutant protein, loss of 53BP1, RIF1 or REV7, loss of PARP-1 and increased drug efflux. 1 However, many issues on tumor drug resistance to PARPi remain to be clarified.
The present knowledge about PARPi resistance comes primarily from the studies on the olaparib-induced resistance in BRCA or ATMdefective cancer cells. 1 We have only very limited understanding regarding the characteristics of drug resistance of the same cancer cells to different PARPi and their cross-resistance profiles. Moreover, little is known about the characteristics and mechanisms of PARPi resistance in non-BRCA/ATM-defective cancer cells. There have been 3 PARPi approved for clinical cancer therapy and many others in clinical trials. 1, 4, 5 Moreover, PARPi will probably be used to treat non-BRCAdefective cancers in the future. Therefore, the answers to these issues will be critical to understanding, monitoring, delaying and even preventing PARPi resistance in different clinical settings.
Phosphatase and tensin is one of the most frequently mutated genes in a wide range of hereditary and sporadic human tumors, including glioblastoma. Up to 70% of glioblastoma patients are defective for PTEN due to loss of 1 allele of the long arm of chromosome 10 on which PTEN is located. 6 PTEN is important for the expression of RAD51, a critical HRR factor, and, thus, PTEN deficiency results in defective HRR. 7 PTEN-deficient tumor cells are sensitive to PARPi. [8] [9] [10] [11] For example, PTEN-deficient glioblastoma U87MG and U251 cells show different degrees of sensitivity to olaparib, 12-14 simmiparib 13 and mefuparib hydrochloride. 14 The U251 cell line has been used extensively and its sensitivity to PARPi, including olaparib and simmiparib, is higher than that of the U87MG cell line. 13 Olaparib is the first approved PARPi, 1 talazoparib has been shown to be the most potent PARPi so far 10 and is undergoing phase III clinical trials, 15 and simmiparib is one of new PARPi developed by our institute and is currently in phase I clinical trials. 13 These 3 inhibitors may represent the existing PARPi that possess different characteristics and are in different clinical stages.
In the present study, we separately exposed U251 cells to ola- 
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Details are provided in Document S1.
13,16
| Proliferation inhibition assays
Proliferation inhibition was determined by sulforhodamine B (SRB) assay, as described previously. 17 
| Growth rate assays
The growth rate of both U251 parental and resistant cells was determined using SRB assays. 18 
| Transwell migration and invasion assays
| DNA sequencing
| Western blotting
Western blotting was performed using the standard procedure.
| Cell cycle assays
Cell cycle arrest was analyzed by propidium iodide-staining-based flow cytometry as described previously. 13 
| Immunofluorescence
| Transfection with 53BP1 plasmids
| Quantitative real-time PCR
Details are provided in Document S1. The data show that the resistant variants are more resistant to the PARPi to which the parental U251 cells are more sensitive. Notably, once generated, the resistant cells did not need to be maintained with Secondary mutations on mutated BRCA1 or BRCA2 have been shown to be potential PARPi-resistant mechanisms. 1, 19, 20 The U251 cell line harbors a protein-truncating c.720_721 insTT frameshift mutation, which results in lack of PTEN expression. 21 This frameshift mutation on PTEN (c.720_721 insTT) was retained in all the 3
PARPi-resistant variants revealed by whole-exome sequencing (Figure 2D) . Indeed, the resistant and parental cells did not express the PTEN protein ( Figure 2E ). In these cells, moreover, all the exons of BRCA1, BRCA2, ATM and TP53 showed no differences (Table S1 ).
PTEN regulates the Akt-mTOR-ribosomal protein S6 signaling axis and phosphorylation of S6 has been reported to participate in PARPi resistance. 22 However, the levels of the components in this signaling axis, including Akt, p-S473-Akt and S6, p-S235/236-S6 or p-S240/ 244-S6, showed no differences in the resistant and parental cells ( Figure 2F ). The result indicates that PARPi resistance is independent of the PTEN-Akt-mTOR-S6 signaling axis in these variants.
In addition, overexpression of drug transporters such as P-gp might contribute to olaparib resistance. 1 However, all the PARPiresistant variants, just as their parental cells, did not express P-gp or BCRP ( Figure 2G ). Phosphatase and tensin homolog (PTEN)-deficient glioblastoma U251 cells were separately exposed to increasing concentrations of olaparib (OP), talazoparib (TP) and simmiparib (SP). The resulting PARPi-resistant variants were denoted by U251/OP, U251/TP and U251/SP, respectively. B,C, PARPi-resistance profiles. Cells were exposed to olaparib (OP), talazoparib (TP), simmiparib (SP), niraparib (NP) or rucaparib (RP) for 7 days and then subjected to sulforhodamine B (SRB) assays. The IC 50 value was expressed as mean AE SD from 3 separate experiments and the resistance factor was calculated as the ratio of the averaged IC 50 value of the indicated PARPi in the given resistant cells to that of the same PARPi in the parental U251 cells. B shows the resistance of a given PARPi-resistant variant to the PARPi that was used to establish the variant while C indicates the cross-resistance to the PARPi that were not used to establish the indicated variant. D, Growth curves of the resistant and parental U251 cells. Samples were determined by the SRB assay and their optic density (OD) values were normalized using that of the parental U251 group on day 1 (relative OD). E, representative images of cell migration from 3 independent Transwell migration assays. 1, U251; 2, HUVEC; 3, U251/OP; 4, U251/TP; 5, U251/SP. Scale bar: 50 lm. the resistance of all the 3 resistant variants to the rest tested drugs including cisplatin was lower than 2-fold ( Figure 5A ). In contrast to the resistance profile of the PARPi-resistant variants to PARPi, therefore, our data showed a unique cross-resistance profile to those non-PARPi anticancer drugs.
Consistent with its drug resistance, Ara-C induced much less cH2AX in the 3 resistant variants than in the parental U251 cells ( Figure 5B ). SAMHD1, a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, has been shown to be a biomarker for Ara-C sensitivity in acute myeloid leukemia. 23, 24 Interestingly, all 3 resistant variants expressed much more SAMHD1 mRNA ( Figure 5C ) and protein ( Figure 5D ) than the parental cells. Importantly, depletion of SAMHD1 by using the CRISPR/Cas9 technique ( Figure 5E ) almost F I G U R E 3 Cell cycle arrest and cH2AX accumulation in U251/OP cells exposed to olaparib. A,B, G2/M arrest induced by olaparib was decreased determined by FACS. A, Representative histograms; in the inserts, •, □ and ▲ show the percentage of cells in G0/G1, S and G2/M phases, respectively. B, Percentage of cells in the G2/M phase expressed as mean AE SD from 3 independent experiments. **P < .01. C-E, Levels of cellular cH2AX were reduced in U251/OP cells exposed to olaparib. Both U251 and U251/OP cells were treated with olaparib for 24 hours and then subjected to western blotting (C) and confocal microscopy (D). Scale bar in d: 5 lm. Cells that contained 5 or more cH2AX foci per nucleus were considered cH2AX-positive cells. At least 50 cells were analyzed in each group. The data were expressed as mean AE SD from 3 independent experiments (E). *P < 0.05; **P < .01. F, Levels of cellular cH2AX induced by irradiation (IR; 10 Gy) were decreased in U251/OP cells determined by western blotting completely restored the sensitivity of U251/OP to Ara-C ( Figure 5F ).
Similar results were obtained in both U251/TP and U251/SP cells ( Figure S7A ). However, depletion of SAMHD1 did not sensitize the PARPi-resistant cells to PARPi (Figures 5G and S7B ).
| DISCUSSION
As PARPi are increasingly being used for cancer therapy, understanding their resistance is becoming more and more significant and urgent. In fact, clinical resistance to PARPi, including olaparib, 25 rucaparib 26 and veliparib, 27 has been reported. In addition, PARPi will probably extend their application to non-BRCA/ATM-mutated cancers. 1 Although different PARPi, such as olaparib, rucaparib, niraparib and talazoparib, have similar PARP1 inhibition activity, they display differential capacity in trapping PARP1-DNA complexes. 1, 28 Moreover, different from other PARPi, niraparib elicits its anticancer effects appearing in a manner of relatively low dependency on HR deficiency in either animal models 29 or patients. 30 However, current studies primarily focus on the resistance to only one PARPi, for F I G U R E 4 Exogenous expression of 53BP1 partially restored the sensitivity of poly(ADP-ribose) polymerase inhibitors (PARPi)-resistant variants to PARPi. A, Levels of DNA repair-related proteins in the parental and resistant U251 cells determined by western blotting. B, After U251/OP, U251/TP and U251/SP cells were transfected with the full-length 53BP1 cDNA, the levels of 53BP1 protein were determined by western blotting (upper) and immunofluorescence (lower). Scale bar: 5 lm. C, Accumulation of cH2AX triggered by olaparib was increased in U251/OP+53BP1 cDNA cells relative to U251/OP cells. D,E, Exogenous expression of 53BP1 in U251/OP cells partially restored olaparib sensitivity. D, Survival curves of olaparib-treated U251, U251/OP and U251/OP+53BP1 cDNA cells. E, IC 50 in the log scale. **P < .01 F I G U R E 5 Upregulation of SAMHD1 was associated with the resistance of poly(ADP-ribose) polymerase inhibitors (PARPi)-resistant variants to Ara-C. A, Cells were treated with the indicated drugs for 72 hours and then subjected to sulforhodamine B (SRB) assays. IC 50 values (left panel) were calculated from 3 independent experiments and expressed as mean AE SD. The resistance factor (right panel) is the ratio of the averaged IC 50 value of the indicated drug in the given resistant cells to that of the same drug in the parental U251 cells. b, Levels of c-H2AX induced by Ara-C reduced in the resistant cells determined by western blotting. C, mRNA level of SAMHD1 was detected by qRT-PCR and normalized using that of the parental U251 cells. **P < .01; ***P < .001. D, Protein level (upper) and distribution (lower) of SAMHD1 detected by western blotting and immunofluorescence, respectively. Scale bar: 5 lm. E, CRISPR/Cas9-mediated knockout of SAMHD1 in U251/OP cells was confirmed by western blotting. f,g, cells were treated with Ara-C for 3 days (F) or PARPi for 7 days (G) and then subjected to SRB assays. Data from 3 independent experiments were expressed as mean AE SD example, olaparib. Here, we present the first report on the resistance of PTEN-deficient glioblastoma cells to three different PARPi simultaneously.
In this study, we generated 3 different PARPi-resistant variants of U251 cells (U251/OP, U251/TP and U251/SP) with olaparib, talazoparib and simmiparib by concentration-increased induction. In addition to the PARPi that was used to establish the corresponding resistant cells, all these variants were cross-resistant to the other tested PARPi; that is, olaparib, rucaparib, niraparib, talazoparib and simmiparib. Notably, the PARPi resistance profile reveals that the resistant variants appear to possess higher degrees of resistance to the PARPi to which the parental U251 cells are more sensitive.
However, this might not indicate that the cancers resistant to the former can be treated with the latter because anticancer drugs are generally used clinically at their maximum tolerated doses. It is also worthwhile noting that the PARPi resistance in our case is character- PARPi-resistant cancers but also for explorations on the drug resistance mechanisms. In contrast, some drugs in our test such as cisplatin have been reported to be cross-resistant to PARPi in both clinical 27 and preclinical studies. [31] [32] [33] [34] However, cisplatin was shown not to be cross-resistant to rucaparib in ovarian cancers defective for nonhomologous end joining. 35 Mechanistic studies reveal that all the PARPi-resistant variants, when compared with the parental U251 cells, display no significant changes in the levels of PARP1-3, and tankyrase1/2, the formation of PAR, mutations on PTEN, BRCA1, BRCA2, ATM and TP53 genes, the levels of PTEN and the members in the related Akt-mTOR-S6 signaling axis and the expression of drug transporters P-gp and BCRP. The data indicate that these factors, some of which have been reported to be correlated to PARPi resistance, 1, 36 -deficient breast [37] [38] [39] 41 or ovarian cancer cells. 40 For the first time, our results reveal that loss of 53BP1 also dominantly mediates the resistance of PTEN-deficient glioblastoma cells to different PARPi, strongly suggesting that loss of 53BP1 is a relatively universal mechanism responsible for PARPi resistance at different conditions. The data also indicate a possibility of the combination of 53BP1 levels with PTEN deficiency, just as with BRCA1 deficiency, as a biomarker to predict PARPi sensitivity. 37 In addition, we further demonstrate that SAMHD1 is responsible for the resistance of all 3 PARPi-resistant U251 variants to Ara-C evidenced by its knockout completely restoring the Ara-C sensitivity.
However, SAMHD1 seems not to be correlated to their PARPi resistance because its knockout did not change the sensitivity of the variants to PARPi. However, the exogenous expression of 53BP1 in the PARPi-resistant variants did not affect their sensitivity to Ara-C (Supplementary Figure S7C) . This is interesting because the loss of At present, PARPi are being tested for the treatment of glioblastoma in clinical trials. 42, 43 Recently, the PARPi olaparib was reported to be found in the core of the tumors in 27 of 35 glioblastoma patients. In 10 of the 27 patients, moreover, olaparib was found to reach tumor cells in the neighboring regions. 44 The results suggest a great possibility of PARPi for the treatment of glioblastoma. In addition, other PTENdefective tumors, such as prostate and endometrial cancers, have been shown to be sensitive to PARPi. 1, [8] [9] [10] [11] Therefore, our findings in this study could lead in a second step to ancillary studies in clinical research to evaluate PARPi in glioblastoma or other related tumor subtypes.
Together, our study demonstrates a consistent resistance profile to PARPi and a unique cross-resistance profile to non-PARP conventional anticancer drugs in 3 PARPi-resistant variants generated from PTEN-deficient glioblastoma U251 cells induced by different PARPi.
